You just read:

Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY™ (Romosozumab) In Postmenopausal Women With Osteoporosis

News provided by

Amgen

21 May, 2017, 18:01 ET